Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patientsYasuhiro Nakamura, N. Yamazaki, Satoshi Fukushima et al.|Annals of Oncology|2020Cited by 140
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)Yasuhiro Nakamura, Naoya Yamazaki, Kenjiro Namikawa et al.|ESMO Open|2021Cited by 57
Anti-PD-1 antibody therapy for epithelial skin malignanciesM Ishii, Takeru Funakoshi, Ikuko Hirai et al.|Medicine|2020Cited by 24